OÜ PharmaFourteenRegistered
Going concern uncertainty. In the 2021 report the auditor pointed to material uncertainty about the company's ability to continue as a going concern.
Qualified audit opinion. 2021 report: Qualified.
Key figures
6 171 108 €+2,6%
Revenue 2025
+13,1%
Average annual growth 2020–2025
Ratios
20250,1%
Profit margin
2,0%
EBITDA margin
−19,9%
Equity ratio
0,5×
Current ratio
−1,2%
Return on equity
750 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 1 573 777 € | 18 | 17 075 € |
| Q1 2026 | 1 657 071 € | 18 | 17 315 € |
| Q4 2025 | 1 607 257 € | 17 | 17 991 € |
| Q3 2025 | 1 464 172 € | 16 | 19 766 € |
| Q2 2025 | 1 508 340 € | 13 | 17 763 € |
| Q1 2025 | 1 566 524 € | 13 | 17 801 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2020–2025
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Balance sheet — assets | ||||||
| Total current assets | 746 839 | 785 648 | 1 166 568 | 973 013 | 836 462 | 865 720 |
| Total non-current assets | 1 547 773 | 1 380 413 | 1 213 052 | 830 293 | 621 226 | 502 897 |
| Total assets | 2 294 612 | 2 166 061 | 2 379 620 | 1 803 306 | 1 457 688 | 1 368 617 |
| Balance sheet — liabilities and equity | ||||||
| Current liabilities | 2 646 510 | 2 390 121 | 2 676 216 | 2 097 098 | 1 733 012 | 1 640 784 |
| Non-current liabilities | — | — | — | — | — | — |
| Total liabilities | 2 646 510 | 2 390 121 | 2 676 216 | 2 097 098 | 1 733 012 | 1 640 784 |
| Share capital | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| Retained earnings of previous periods | — | −354 398 | −226 559 | −299 096 | −296 292 | −277 824 |
| Profit for the year | −354 398 | 127 838 | −72 537 | 2804 | 18 468 | 3157 |
| Total equity | −351 898 | −224 060 | −296 596 | −293 792 | −275 324 | −272 167 |
| Income statement | ||||||
| Sales revenue | 3 340 561 | 5 046 991 | 5 543 790 | 6 142 509 | 6 017 202 | 6 171 108 |
| Operating profit | −354 399 | 127 836 | −72 543 | 2788 | 18 462 | 3153 |
| EBITDA | −228 911 | 295 197 | 94 818 | 135 634 | 139 210 | 121 482 |
| Profit before income tax | −354 398 | 127 838 | −72 537 | 2804 | 18 468 | 3157 |
| Profit for the reporting year | −354 398 | 127 838 | −72 537 | 2804 | 18 468 | 3157 |
| Labour costs | 59 250 | 59 288 | 146 090 | 186 226 | 166 069 | 168 900 |
| Depreciation of non-current assets | 125 488 | 167 361 | 167 361 | 132 846 | 120 748 | 118 329 |
| Other indicators | ||||||
| Employees | 2 | 1 | 3 | 3 | 3 | 4 |
| Calculated dividend | — | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
Click a node to see its other connections.
CompanyPersonShareholderOther roleAdditional link
Annual reportsPDF, XBRL
Loading list of reports…
Source: e-Business Register (RIK). Files open/download directly from the official register.
Related companies
Same activity — Ravimite jaemüük